News
Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...
For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...
Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...
Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.
5d
ZME Science on MSNOzempic Is Changing More Than Waistlines as Scientists Wise Up to Concerning Side EffectsAnimal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...
According to a new report from Big Chalk Analytics, GLP-1 users have cut $6.5 billion from U.S. grocery spend.
Men were three times more likely than women to say GLP-1s boosted their confidence and two times more likely to say they were going on more dates. They also reported higher libido, more matches and ...
1d
The Hearty Soul on MSNA New Ozempic-like drug Side Effect Has Just Been Discovered-And It's Turning Lives Upside DownMedications such as Ozempic and Saxenda have grown in popularity due to their ability to treat type 2 diabetes and assist in weight loss. These medications belong to a class of drugs known as GLP-1 ...
A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...
2d
New Scientist on MSNYou don't need to take drugs like Ozempic consistently to lose weightPeople who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which may reassure users when the therapies are in short supply.
The goal with ProKidney Corp.'s rilparencel-branded therapy is "to demonstrate the therapy's potential to preserve kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results